Lifson N, Salloum G, Kurochkin P, Bivona M, Yin HY, Alpert S, et al.
Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc. Date of publication 2021 Oct 1;volume 48(4):425-430.
1. Undersea Hyperb Med. 2021 Fourth Quarter;48(4):425-430.
Treatment outcomes on neovascularization after CRAO treated with hyperbaric
oxygen.
Lifson N(1), Salloum G(1), Kurochkin P(1), Bivona M(1), Yin HY(1), Alpert S(1).
Author information:
(1)Department of Ophthalmology, State University of New York Upstate Medical
Center, Syracuse, New York, U.S.
Central retinal artery occlusion (CRAO) is a condition that causes sudden vision
loss due to obstruction of the retinal artery, typically from a thrombotic or
embolic source. It is often associated with atherosclerotic risk factors,
including cardiovascular disease, diabetes, hyperlipidemia, and a history of
cerebrovascular disease. CRAO often leads to a poor visual outcome as well as
neovascularization of the iris, retina, and optic disc, which can exacerbate
vision loss and cause pain. While there are several treatment modalities for
CRAO, few have been proven to be effective in decreasing the effects of
neovascularization. The use of hyperbaric oxygen (HBO2) therapy is often used in
the treatment of CRAO due to its ease of use and relatively benign side effect
profile. This study aims to assess the degree of improvement in visual acuity
(VA) and neovascularization following HBO2. Our data ultimately shows that 20%
of patients developed neovascularization after HBO2 compared to 29.8% of those
who did not undergo HBO2 (p<.05). Our findings suggest that HBO2 has a
statistically significant protective effect against neovascularization and may
improve long-term visual acuity.
Copyright© Undersea and Hyperbaric Medical Society.
PMID: 34847306 [Indexed for MEDLINE]
Conflict of interest statement: The authors of this paper declare no conflicts
of interest exist with this submission.
